Amgen steers PCSK9 blockbuster hopeful through another promising PhIII, but the critical test is looming
Amgen took another step down a long path aimed at outlining the health advantages offered by its PCSK9 drug Repatha. In a Phase III study, researchers for the company said that the drug hit the primary endpoint, significantly reducing the need for a procedure known as apheresis, which is used to counter high LDL levels in certain at-risk patients.
The drug, already approved to control cholesterol, also met secondary endpoints on the percent change from baseline to week 4 in LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C) and total cholesterol: HDL-C ratio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.